Business Wire

TOURISE and Oxford Economics Release White Paper Charting Tourism’s Path to Resilience and Stability Amid Global Volatility

Share

TOURISE, in collaboration with Oxford Economics, has released a new white paper titled “Growth Amid Uncertainty: Opportunities and Risks on the Road to 2 Billion Global Travellers,” unveiled during the inaugural TOURISE Summit. The publication presents key opportunities and risks that the industry will face in coming years as well as a framework to guide policymakers, destination leaders, and industry stakeholders in strengthening the tourism sector’s capacity to withstand global disruptions and foster long-term sustainability and resilience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110254503/en/

TOURISE and Oxford Economics Release White Paper Charting Tourism’s Path to Resilience and Stability Amid Global Volatility

The white paper underscores the imperative of resilience as a foundational principle for tourism development in an era marked by geopolitical shifts, climate-related challenges, and evolving traveler expectations.

“Tourism has always been a force for connection and opportunity, but its true strength lies in its capacity to evolve and remain resilient. This white paper provides a clear direction for how the global tourism sector can navigate the years ahead, guiding us toward a future of sustainable growth and shared prosperity,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism and Chairman of TOURISE.

“It demonstrates how data-driven planning and forward-looking policy can help destinations manage growth responsibly, withstand shocks, and continue creating jobs and opportunities. As we move toward two billion travelers by 2030, our focus must be on building a tourism ecosystem that is resilient, inclusive, and prepared for the challenges and possibilities of a changing world.”

Drawing on extensive data and economic modeling, the report identifies key trends shaping the future of travel and tourism. It highlights the growing importance of evidence-based decision-making and adaptive policy frameworks to ensure destinations remain competitive and inclusive.

“Resilience in tourism begins with clarity, which comes from hard-hitting data,” said Adam Sacks, President of Tourism Economics, an Oxford Economics company. “This white paper provides a data-driven roadmap for navigating uncertainty, enabling destinations to make informed choices and invest with confidence.”

Among its findings, the report projects a significant increase in international arrivals, rising from 1.5 billion today to 2 billion by 2030, driven in part by changing traveler preferences, with a marked emphasis on experiential value over cost. Tourists are increasingly seeking immersive, culturally authentic experiences, contributing to longer stays and higher per-trip spending.

To accommodate this demand, destinations that proactively include strategies such as adopting open visa regimes, traveler-centric policies, and forward-looking infrastructure are projected to be best positioned to capture a forecasted 40% increase in global travel demand by 2030.

This joint initiative reflects TOURISE’s ongoing commitment to fostering a tourism sector that is resilient, data-informed, and prepared to meet the challenges of a rapidly changing world.

Download the full white paper at TOURISE.com.

About TOURISE

TOURISE is the world’s premier platform shaping a new horizon for global tourism.

Under the umbrella of the Saudi Ministry of Tourism, powered by the Saudi Tourism Authority, the inaugural TOURISE Summit will take place November 11–13, 2025, in Riyadh, Saudi Arabia.

The event will convene visionaries from government, business, investment, tourism, and technology to drive transformative deals and deliver high-impact initiatives that redefine the future of the global tourism industry.

TOURISE ensures worldwide participation while offering access to decision-makers shaping the industry’s evolution. Following the Summit, TOURISE will continue as a year-round platform where bold ideas turn into real-world solutions.

This is where the next 50 years of tourism are shaped. Together, we are unstoppable.

For more information visit www.tourise.com.

About Oxford Economics

Oxford Economics is the world’s foremost independent economic advisory firm. Covering over 200 countries, 100 industrial sectors and 8,000 cities and regions, we provide insights and solutions that empower clients to make informed decisions faster in an increasingly complex and uncertain world.

For more information, visit https://www.oxfordeconomics.com/us/

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110254503/en/

Contacts

For media inquiries, please contact: press@oxfordeconomics.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press Release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press Release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye